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Purpose of the study
Zidovudine is an antiretroviral nucleoside analogue
reverse transcriptase inhibitor (NRTI). Long-term use of
zidovudine is linked to a cardiomyopathy and various
other tissue toxicities, which are associated with mito-
chondrial DNA (mtDNA) depletion. Because zidovudine
inhibits thymidine kinases, the mechanism of mtDNA
depletion may involve a restriction in the availability of
phosphorylated pyrimidine nucleosides which are
required as mtDNA and mtRNA building blocks. We
investigated if the cardiomyopathy is a class effect of
antiretroviral nucleoside analogues, and if the mitochon-
drial cardiotoxicity can be prevented with uridine as a
pyrimidine nucleotide precursor.
Methods
Balb/c mice were fed with zidovudine (100 mg/kg/day) or
zalcitabine (13 mg/kg/day). Mice were co-treated with or
without Mitocnol (340 mg/kg/day), a dietary supplement
with high uridine bioavailability. Cardiac muscle was
examined after 9 weeks of treatment.
Summary of results
Zidovudine and zalcitabine both induced mitochondrial
cardiotoxicity. Compared to untreated controls, the his-
topathological cardiomyopathy score was increased after
treatment with zalcitabine (312%, p < 0.001) and zidovu-
dine (540%, p < 0.001). Mitochondria were enlarged and
their crystal architecture was disrupted. The organelles
contained low mtDNA copy numbers (zidovudine 87.1%,
p = 0.02, zalzitabine 86.4%, p = 0.01; compared to con-
trols) and reduced cytochrome C-oxidase (COX) activity.
The expression of the mtDNA-encoded COX I subunit,
but not of nucleus encoded COX IV protein, was
impaired. Uridine supplementation attenuated or nor-
malized all pathology and had no intrinsic effects.
Conclusion
Both zidovudine and zalcitabine induced a mitochondrial
cardiomyopathy, which is antagonized by uridine supple-
mentation. The results provide proof of the importance of
pyrimidine pools in the pathogenesis of zidovudine cardi-
omyopathy. As uridine supplementation is tolerated well
by humans, this strategy should be investigated in clinical
trials.
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